StreetInsider.com News Articles

Form 4 DarioHealth Corp. For: Sep 24 Filed by: PALUMBO JOHN R

Mon, 28 Sep 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260928/27114524.html

Form 4 DarioHealth Corp. For: Aug 12 Filed by: Shaked Yoav

Mon, 28 Sep 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260928/27114511.html

Form 4 DarioHealth Corp. For: Sep 24 Filed by: MCGRATH DENNIS M

Mon, 28 Sep 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260928/27114514.html

Form 4 DarioHealth Corp. For: Sep 18 Filed by: STERN ADAM K

Mon, 28 Sep 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260928/27114517.html

Form 4 DarioHealth Corp. For: Sep 24 Filed by: Karah Hila

Mon, 28 Sep 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260928/27114492.html

Form 4 DarioHealth Corp. For: Sep 24 Filed by: Franco-Yehuda Chen

Mon, 28 Sep 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260928/27114498.html

Form 4 DarioHealth Corp. For: Sep 24 Filed by: Matheis Dennis

Mon, 28 Sep 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260928/27114501.html

Form 3 DarioHealth Corp. For: Sep 24 Filed by: Sherman Lara Ann

Mon, 28 Sep 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260928/27114476.html

Form 4 DarioHealth Corp. For: Aug 12 Filed by: Raphael Erez

Mon, 28 Sep 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260928/27114480.html

DarioHealth wins New Jersey health plan contract via Amwell

Thu, 17 Sep 2026 07:32:24 -0400

DarioHealth Corp. (NASDAQ: DRIO) announced a new contract with a New Jersey health plan representing approximately 1.5 million covered lives, secured through its channel partnership with Amwell. The program is expected to launch and begin generating revenue in the first quarter of 2027.

The New Jersey plan operates as an administrative services only (ASO) health plan, giving DarioHealth access to self-funded employer groups that can deploy its cardiometabolic solutions. The contract marks the third large state health plan signed through Amwell in the past 12 months, following agreements in Arizona and Florida.

"This is exactly the type of scale we envisioned when

Dario Wins Contract with One of New Jersey's Largest Health Plans Representing 1.5 Million Covered Lives

Thu, 17 Sep 2026 07:30:00 -0400

Agreement secured through channel partner Amwell significantly expands Dario's reach through its channel distribution strategy

Program for Dario's cardiometabolic suite and provider-backed care expected to launch with the customer and begin generating revenue in the first quarter of 2027

Marks the third large state health plan signed through Amwell in

Dario Wins Contract with One of New Jersey's Largest Health Plans Representing 1.5 Million Covered Lives

Thu, 17 Sep 2026 07:30:00 -0400

Agreement secured through channel partner Amwell significantly expands Dario's reach through its channel distribution strategy

Program for Dario's cardiometabolic suite and provider-backed care expected to launch with the customer and begin generating revenue in the first quarter of 2027

Marks the third large state health plan signed through Amwell in

Form 8-K DarioHealth Corp. For: Aug 20

Fri, 21 Aug 2026 16:06:00 -0400
si-local-file:///var/storage/secattach/20260821/26961396.html

Form 8-K DarioHealth Corp. For: Aug 20

Fri, 21 Aug 2026 16:06:00 -0400
si-local-file:///var/storage/secattach/20260821/26961396.html

Alliance Global Partners Starts DarioHealth Corp. (DRIO) at Buy

Wed, 19 Aug 2026 07:08:55 -0400

Alliance Global Partners analyst Scott Henry initiates coverage on DarioHealth Corp. (NASDAQ: DRIO) with a Buy rating and a price target of $12.00.
For an analyst ratings summary and ratings history on DarioHealth Corp. click here. For more ratings news on DarioHealth Corp. click here.
Shares of DarioHealth Corp. closed at $7.18 yesterday.

DarioHealth Corp. (DRIO) PT Lowered to $8 at TD Cowen

Wed, 12 Aug 2026 09:43:53 -0400
TD Cowen analyst Charles Rhyee lowered the price target on DarioHealth Corp. (NASDAQ: DRIO) to $8.00 (from $11.00) while maintaining a rating.

DarioHealth (DRIO) Tops Q2 EPS by 40c

Tue, 11 Aug 2026 06:39:58 -0400

DarioHealth (NASDAQ: DRIO) reported Q2 EPS of ($0.85), $0.40 better than the analyst estimate of ($1.25). Revenue for the quarter came in at $5.18 million versus the consensus estimate of $6.03 million.
For earnings history and earnings-related data on DarioHealth (DRIO) click here.

DarioHealth Reports Second Quarter 2026 Financial Results

Tue, 11 Aug 2026 06:30:00 -0400

Second quarter 2026 revenue was $5.2 million, reflecting the Company's strategic decision to discontinue certain pharmaceutical-related business
Gross margin increased to 62%, compared to 57% in the first quarter of 2026 and 55% in the second quarter of 2025; non-GAAP B2B2C gross margin was approximately 80% for the 10th consecutive quarter
Operating loss decreased by 30% year-over-year and 11% quarter-over-quarter
Operating expenses declined by 21% year-over-year and 8% quarter-over-quarter
Multi-condition strategy compounding: more than 80% of the $13.1 million in contracted and late-stage annual recurring revenue ("ARR") is multi-condition
Commercial momentum with three significant wins in recent weeks, led by a top-5 national

DarioHealth Reports Second Quarter 2026 Financial Results

Tue, 11 Aug 2026 06:30:00 -0400

Second quarter 2026 revenue was $5.2 million, reflecting the Company's strategic decision to discontinue certain pharmaceutical-related business
Gross margin increased to 62%, compared to 57% in the first quarter of 2026 and 55% in the second quarter of 2025; non-GAAP B2B2C gross margin was approximately 80% for the 10th consecutive quarter
Operating loss decreased by 30% year-over-year and 11% quarter-over-quarter
Operating expenses declined by 21% year-over-year and 8% quarter-over-quarter
Multi-condition strategy compounding: more than 80% of the $13.1 million in contracted and late-stage annual recurring revenue ("ARR") is multi-condition
Commercial momentum with three significant wins in recent weeks, led by a top-5 national

DarioHealth Reports Second Quarter 2026 Financial Results

Tue, 11 Aug 2026 06:30:00 -0400

Second quarter 2026 revenue was $5.2 million, reflecting the Company's strategic decision to discontinue certain pharmaceutical-related business
Gross margin increased to 62%, compared to 57% in the first quarter of 2026 and 55% in the second quarter of 2025; non-GAAP B2B2C gross margin was approximately 80% for the 10th consecutive quarter
Operating loss decreased by 30% year-over-year and 11% quarter-over-quarter
Operating expenses declined by 21% year-over-year and 8% quarter-over-quarter
Multi-condition strategy compounding: more than 80% of the $13.1 million in contracted and late-stage annual recurring revenue ("ARR") is multi-condition
Commercial momentum with three significant wins in recent weeks, led by a top-5 national

DarioHealth Reports Second Quarter 2026 Financial Results

Tue, 11 Aug 2026 06:30:00 -0400

Second quarter 2026 revenue was $5.2 million, reflecting the Company's strategic decision to discontinue certain pharmaceutical-related business
Gross margin increased to 62%, compared to 57% in the first quarter of 2026 and 55% in the second quarter of 2025; non-GAAP B2B2C gross margin was approximately 80% for the 10th consecutive quarter
Operating loss decreased by 30% year-over-year and 11% quarter-over-quarter
Operating expenses declined by 21% year-over-year and 8% quarter-over-quarter
Multi-condition strategy compounding: more than 80% of the $13.1 million in contracted and late-stage annual recurring revenue ("ARR") is multi-condition
Commercial momentum with three significant wins in recent weeks, led by a top-5 national

DarioHealth Reports Second Quarter 2026 Financial Results

Tue, 11 Aug 2026 06:30:00 -0400

Second quarter 2026 revenue was $5.2 million, reflecting the Company's strategic decision to discontinue certain pharmaceutical-related business
Gross margin increased to 62%, compared to 57% in the first quarter of 2026 and 55% in the second quarter of 2025; non-GAAP B2B2C gross margin was approximately 80% for the 10th consecutive quarter
Operating loss decreased by 30% year-over-year and 11% quarter-over-quarter
Operating expenses declined by 21% year-over-year and 8% quarter-over-quarter
Multi-condition strategy compounding: more than 80% of the $13.1 million in contracted and late-stage annual recurring revenue ("ARR") is multi-condition
Commercial momentum with three significant wins in recent weeks, led by a top-5 national

DarioHealth Reports Second Quarter 2026 Financial Results

Tue, 11 Aug 2026 06:30:00 -0400

Second quarter 2026 revenue was $5.2 million, reflecting the Company's strategic decision to discontinue certain pharmaceutical-related business
Gross margin increased to 62%, compared to 57% in the first quarter of 2026 and 55% in the second quarter of 2025; non-GAAP B2B2C gross margin was approximately 80% for the 10th consecutive quarter
Operating loss decreased by 30% year-over-year and 11% quarter-over-quarter
Operating expenses declined by 21% year-over-year and 8% quarter-over-quarter
Multi-condition strategy compounding: more than 80% of the $13.1 million in contracted and late-stage annual recurring revenue ("ARR") is multi-condition
Commercial momentum with three significant wins in recent weeks, led by a top-5 national

Form 10-Q DarioHealth Corp. For: Jun 30

Tue, 11 Aug 2026 06:08:00 -0400
si-local-file:///var/storage/secattach/20260811/26900719.html

Form 10-Q DarioHealth Corp. For: Jun 30

Tue, 11 Aug 2026 06:08:00 -0400
si-local-file:///var/storage/secattach/20260811/26900719.html